Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Zhang, Chunyu ^a,g   Elkahloun, Abdel G ^b   Robertson, Matthew ^a   Gills, Joell J ^a   Tsurutani, Junji ^a,c   Shih, Joanna H ^a   Fukuoka, Junya ^a,d   Hollander, M Christine ^a   Harris, Curtis C ^a   Travis, William D ^e   Jen, Jin ^a,f   Dennis, Phillip A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOYAMA UNIVERSITY HOSPITAL   (Japan)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MAYO CLINIC   (United States)

^g LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDK1 PROTEIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; NAVELBINE; PACLITAXEL; TUMOR MARKER; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE 1;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL IMMORTALIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOPLASM; DATA BASE; DRUG RESPONSE; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; MICROTUBULE; MITOSIS; PREDICTION; PROTEIN EXPRESSION; VALIDATION STUDY; CHEMISTRY; DRUG RESISTANCE; GENETICS; LUNG TUMOR; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL RATE; TUMOR CELL LINE;

CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE;

EID: 80051955317     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023849     Document Type: Article

References (56)

1. Jemal A, Siegel R, Xu J, Ward E., Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380.
3. Gupta PC, Murti PR, Bhonsle RB, (1996) Epidemiology of cancer by tobacco products and the significance of TSNA. Crit Rev Toxicol 26: 183-198.
4. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, et al. (2002) Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 21: 2418-2424.
5. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, et al. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48: 5738-5741.
6. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692.
7. Dammann R, Li C, Yoon JH, Chin PL, Bates S, et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319.
8. Brognard J, Clark AS, Ni Y, Dennis PA, (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997.
9. Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, et al. (2005) Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis 26: 1182-1195.
10. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, et al. (2003) Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111: 81-90.
11. Hahn WC, Weinberg RA, (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2: 331-341.
12. Reddel RR, Ke Y, Gerwin BI, McMenamin MG, Lechner JF, et al. (1988) Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 48: 1904-1909.
13. Klein-Szanto AJ, Iizasa T, Momiki S, Garcia-Palazzo I, Caamano J, et al. (1992) A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc Natl Acad Sci U S A 89: 6693-6697.
14. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, et al. (2006) Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24: 306-314.
15. Th'ng JP, Wright PS, Hamaguchi J, Lee MG, Norbury CJ, et al. (1990) The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene product. Cell 63: 313-324.
16. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, et al. (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 97: 13103-13107.
17. van den Heuvel S, Harlow E, (1993) Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262: 2050-2054.
18. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, et al. (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092.
19. Singhal S, Amin KM, Kruklitis R, DeLong P, Friscia ME, et al. (2003) Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther 2: 291-298.
20. Schang LM, (2004) Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim Biophys Acta 1697: 197-209.
21. Lodygin D, Hermeking H, (2005) The role of epigenetic inactivation of 14-3-3sigma in human cancer. Cell Res 15: 237-246.
22. Ray D, Terao Y, Nimbalkar D, Hirai H, Osmundson EC, et al. (2007) Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res 67: 6605-6611.
23. Ray D, Terao Y, Fuhrken PG, Ma ZQ, DeMayo FJ, et al. (2007) Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res 67: 984-991.
24. Pereg Y, Liu BY, O'Rourke KM, Sagolla M, Dey A, et al. (2010) Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. Nat Cell Biol 12: 400-406.
25. Kristjansdottir K, Rudolph J, (2004) Cdc25 phosphatases and cancer. Chem Biol 11: 1043-1051.
26. Ferguson AM, White LS, Donovan PJ, Piwnica-Worms H, (2005) Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol Cell Biol 25: 2853-2860.
27. Kallstrom H, Lindqvist A, Pospisil V, Lundgren A, Rosenthal CK, (2005) Cdc25A localisation and shuttling: characterisation of sequences mediating nuclear export and import. Exp Cell Res 303: 89-100.
28. Leisser C, Rosenberger G, Maier S, Fuhrmann G, Grusch M, et al. (2004) Subcellular localisation of Cdc25A determines cell fate. Cell Death Differ 11: 80-89.
29. Donzelli M, Draetta GF, (2003) Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 4: 671-677.
30. Jackman M, Lindon C, Nigg EA, Pines J, (2003) Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 5: 143-148.
31. Pines J, (1999) Four-dimensional control of the cell cycle. Nat Cell Biol 1: E73-79.
32. Golsteyn RM, (2005) Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Lett 217: 129-138.
33. Castedo M, Perfettini JL, Roumier T, Kroemer G, (2002) Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9: 1287-1293.
34. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, et al. (1994) Premature p34cdc2 activation required for apoptosis. Science 263: 1143-1145.
35. Bjorck E, Ek S, Landgren O, Jerkeman M, Ehinger M, et al. (2005) High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 105: 2908-2915.
36. Malumbres M, Barbacid M, (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166.
37. Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, et al. (2007) Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448: 811-815.
38. Vecchione A, Baldassarre G, Ishii H, Nicoloso MS, Belletti B, et al. (2007) Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. Cancer Cell 11: 275-289.
39. Manchado E, Guillamot M, de Carcer G, Eguren M, Trickey M, et al. (2010) Targeting Mitotic Exit Leads to Tumor Regression In Vivo: Modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta Phosphatase. Cancer Cell 18: 641-654.
40. Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, et al. (2008) Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 19: 68-72.
41. Linares JF, Amanchy R, Diaz-Meco MT, Moscat J, (2011) Phosphorylation of p62 by cdk1 controls the timely transit of cells through mitosis and tumor cell proliferation. Mol Cell Biol 31: 105-117.
42. Wei Y, Chen YH, Li LY, Lang J, Yeh SP, et al. (2011) CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol 13: 87-94.
43. Liu D, Huang CL, Kameyama K, Hayashi E, Yamauchi A, et al. (2002) Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Cancer 94: 2239-2247.
44. Niederle N, Ostermann J, Achterrath W, Lenaz L, Schmidt CG, (1991) Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study. Cancer Chemother Pharmacol 28: 59-62.
45. Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, et al. (2003) Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res 9: 4682-4688.
46. Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, et al. (2002) Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 32: 306-311.
47. Honda S, Hayashi M, Kobayashi Y, Ishikawa Y, Nakagawa K, et al. (2003) A role for the pituitary tumor-transforming gene in the genesis and progression of non-small cell lung carcinomas. Anticancer Res 23: 3775-3782.
48. Hanash SM, Strahler JR, Kuick R, Chu EH, Nichols D, (1988) Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem 263: 12813-12815.
49. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC, (2004) Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127.
50. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, et al. (1999) A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104.
51. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, et al. (2003) Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200: 620-626.
52. Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, et al. (2004) Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 15: 1654-1660.
53. Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, et al. (2004) Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 91: 537-540.
54. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, et al. (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14: 457-460.
55. Allander SV, Nupponen NN, Ringner M, Hostetter G, Maher GW, et al. (2001) Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 61: 8624-8628.
56. Zeeberg BR, Qin H, Narasimhan S, Sunshine M, Cao H, et al. (2005) High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics 6: 168.